John Glenn, first American to orbit Earth, dies at 95

December 9, 2016

Dec 9: John Glenn, who became one of the 20th century's greatest explorers as the first American to orbit Earth and later as the world's oldest astronaut, and also had a long career as a US senator, died in Ohio on Thursday at age 95.

JohnGlenn

Glenn, the last surviving member of the original seven American "Right Stuff" Mercury astronauts, died at the James Cancer Hospital at Ohio State University in Columbus, said Hank Wilson, a spokesman at the university's John Glenn College of Public Affairs, which Glenn helped found.

Glenn was credited with reviving US pride after the Soviet Union's early domination of manned space exploration. His three laps around the world in the Friendship 7 capsule on Feb. 20, 1962, forged a powerful link between the former fighter pilot and the Kennedy-era quest to explore outer space as a "New Frontier."

President Barack Obama, who in 2012 awarded Glenn the nation's highest civilian honor, the Presidential Medal of Freedom, said: "With John's passing, our nation has lost an icon."

"When John Glenn blasted off from Cape Canaveral atop an Atlas rocket in 1962, he lifted the hopes of a nation," Obama said in a statement. "And when his Friendship 7 spacecraft splashed down a few hours later, the first American to orbit the Earth reminded us that with courage and a spirit of discovery there's no limit to the heights we can reach together."

President-elect Donald Trump said on Twitter the United States had lost "a great pioneer of air and space in John Glenn. He was a hero and inspired generations of future explorers."

As the third of seven astronauts in NASA's solo-flight Mercury program to venture into space, Glenn became more of a media fixture than the others and was known for his composure and willingness to promote the program.

Glenn's astronaut career, as well as his record as a fighter pilot in World War Two and the Korean War, helped propel him to the US Senate in 1974, where he represented his home state of Ohio for 24 years as a moderate Democrat.

His star was dimmed somewhat by a Senate investigation of several senators on whether special favors were done for a major campaign contributor. He was cleared of wrongdoing.

Glenn's entry into history came in early 1962 when fellow astronaut Scott Carpenter bade him "Godspeed, John Glenn" just before the Ohio native was rocketed into space for a record-breaking trip that would last just under five hours.

'View is tremendous'

"Zero-G (gravity) and I feel fine," was Glenn's succinct assessment of weightlessness several minutes into his mission. "Oh, and that view is tremendous."

After splashdown and recovery in the Atlantic, Glenn was treated as a hero, addressing a joint session of Congress and feted in a New York ticker-tape parade.

Glenn had been hospitalized since Nov. 25. He "died peacefully," according to a statement from his family and Ohio State University. "He left this earth for the third time as a happy and fulfilled person," the statement said.

"Glenn's extraordinary courage, intellect, patriotism and humanity were the hallmarks of a life of greatness. His missions have helped make possible everything our space program has since achieved and the human missions to an asteroid and Mars that we are striving toward now," NASA Administrator Charles Bolden said.

Glenn's experiences as a pioneer astronaut were chronicled in the book and movie "The Right Stuff," along with the other Mercury pilots. The book's author, Tom Wolfe, called Glenn "the last true national hero America has ever had."

"I don't think of myself that way," Glenn told the New York Times in 2012 to mark the 50th anniversary of his flight. "I get up each day and have the same problems others have at my age. As far as trying to analyze all the attention I received, I will leave that to others."

Glenn's historic flight made him a favorite of President John F. Kennedy and his brother Robert, who encouraged him to launch a political career that finally took off after a period as a businessman made him a millionaire.

Hero status

Even before his Mercury flight, Glenn qualified for hero status, earning six Distinguished Flying Crosses and flying more than 150 missions in World War Two and the Korean War.

After Korea, Glenn became a test pilot, setting a transcontinental speed record from Los Angeles to New York in 1957.

The determination and single-mindedness that marked Glenn's military and space career did not save him from misjudgments and defeat in politics. He lost his first bid for the Senate from Ohio in 1970, after abandoning a race in 1964 because of a head injury suffered in a fall.

He was elected in 1974 and was briefly considered as a running mate for Democratic presidential candidate Jimmy Carter in 1980. But a ponderous address at the Democratic National Convention - people walked out - caused Carter to remark that Glenn was "the most boring man I ever met."

Glenn sought the Democratic presidential nomination himself in 1984 but was quickly eliminated by eventual nominee Walter Mondale, Carter's vice president. His failure was all the more stinging because he had been touted as an early front-runner.

In the Senate, Glenn was respected as a thoughtful moderate with expertise in defense and foreign policy. His luster was dulled, however, by a Senate investigation of the "Keating Five" - five senators suspected of doing favors for campaign contributor Charles Keating Jr. The panel eventually found Glenn did nothing improper or illegal.

Back to space

He took a leading role in seeking to prevent the spread of nuclear weapons, especially to Pakistan. He was the author of a law that forced the United States to impose sanctions on India and Pakistan in 1998 after both countries conducted nuclear tests.

He also was a staunch advocate of a strong military and took a keen interest in strategic issues. He retired from the Senate in 1999.

Thirty-six years after his maiden space voyage, Glenn became America's first geriatric astronaut on Oct. 29, 1998. He was 77 when he blasted off as a mission specialist aboard the shuttle Discovery. He saw it as a blow to the stereotyping of the elderly.

"Maybe prior to this flight, we were looked at as old geezers who ought to get out of the way," Glenn said after his nine-day shuttle mission. "Just because you're up in years some doesn't mean you don't have hopes and dreams and aspirations just as much as younger people do."

John Herschel Glenn Jr. was born on July 18, 1921, in Cambridge, Ohio.

In his latter years, he was an adjunct professor at the John Glenn College of Public Affairs.

He had a knee replacement operation in 2011 and heart surgery in 2014.

Glenn is survived by his wife of 73 years, his childhood sweetheart, Annie Castor. They had two children, David and Lyn.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 19,2020

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 7,2020

Washington, Aug 7: US President Donald Trump on Thursday (local time) signed executive orders halting all transactions with Chinese applications TikTok and WeChat within 45 days, citing national security concerns, further escalating the tensions between Beijing and Washington.

"WeChat, a messaging, social media, and electronic payment application owned by the Chinese company Tencent Holdings Ltd., reportedly has over one billion users worldwide, including users in the United States. Like TikTok, WeChat automatically captures vast swaths of information from its users. 

This data collection threatens to allow the Chinese Communist Party (CCP) access to Americans' personal and proprietary information," Trump said in a statement.

Citing reasons for the ban on WeChat, the US President said that the application captures the personal and proprietary information of Chinese nationals visiting the US, thereby providing the CCP a mechanism to keep tabs on the Chinese citizens who may be "enjoying the benefits of a free society for the first time in their lives".

"In March 2019, a researcher reportedly discovered a Chinese database containing billions of WeChat messages sent from users in not only China but also the United States, Taiwan, South Korea and Australia. WeChat, like TikTok, also reportedly censors content that the CCP deems politically sensitive and may also be used for disinformation campaigns that benefit the CCP. 

These risks have led other countries, including Australia and India, to begin restricting or banning the use of WeChat. The US must take aggressive action against the owner of WeChat to protect our national security," he added.

Earlier, Trump had issued an order banning TikTok as it "reportedly censors content that the CCP deems politically sensitive, such as content concerning protests in Hong Kong and China's treatment of Uighurs and other Muslim minorities. 

TikTok may also be used for disinformation campaigns that benefit the CCP."
US politicians have repeatedly criticised TikTok, owned by Beijing-based startup ByteDance, of being a threat to national security because of its ties to China.

The development comes as China and the US are at loggerheads on a variety of issues including Hong Kong national security law, the South China Sea, the novel coronavirus and trade.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.